CAS: 52198-67-1 - N-(3-Aminopropyl)piperazine trihydrochloride
Formula:C7H20Cl3N3
InChI:InChI=1S/C7H17N3.3ClH/c8-2-1-5-10-6-3-9-4-7-10;;;/h9H,1-8H2;3*1H
InChI key:InChIKey=KGDFJVDYTJSSPC-UHFFFAOYSA-N
SMILES:Cl.NCCCN1CCNCC1
- Synonyms:
- 1-Piperazinepropanamine trihydrochloride
- 1-Piperazinepropanamine, hydrochloride (1:3)
- 3-Piperazin-1-Ylpropan-1-Amine Trihydrochloride
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | N-(3-Aminopropyl)piperazine trihydrochloride REF: IN-DA00DFZYCAS: 52198-67-1 | 97% | 228.00 €~490.00 € | Tue 10 Dec 24 |
 | 1-Piperazinepropanamine 3HCl REF: 54-OR452192CAS: 52198-67-1 | 97% | 432.00 €~960.00 € | Tue 17 Dec 24 |
 | N-(3-Aminopropyl)piperazinetrihydrochloride REF: 3D-FA152226CAS: 52198-67-1 | Min. 95% | To inquire | Tue 21 Jan 25 |
 | 3-(Piperazin-1-yl)propan-1-amine trihydrochloride REF: 10-F763334CAS: 52198-67-1 | 95% | - - - | Discontinued product |
N-(3-Aminopropyl)piperazine trihydrochloride
CAS:52198-67-1
Formula:
C7H20Cl3N3
Purity:
97%
Molecular weight:
252.6128
Ref: IN-DA00DFZY
| 1g | 490.00 € | ||
| 250mg | 228.00 € | ||
| 500mg | 461.00 € |
Estimated delivery in United States, on Tuesday 10 Dec 2024
Ref: 54-OR452192
| 1g | 960.00 € | ||
| 250mg | 432.00 € | ||
| 500mg | 651.00 € |
Estimated delivery in United States, on Tuesday 17 Dec 2024
N-(3-Aminopropyl)piperazinetrihydrochloride
CAS:52198-67-1
Please enquire for more information about N-(3-Aminopropyl)piperazinetrihydrochloride including the price, delivery time and more detailed …
Formula:
C7H20Cl3N3
Purity:
Min. 95%
Molecular weight:
252.61 g/mol
Ref: 3D-FA152226
| 2mg | To inquire | ||
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Tuesday 21 Jan 2025
3-(Piperazin-1-yl)propan-1-amine trihydrochloride
CAS:52198-67-1
Purity:
95%
Molecular weight:
252.61000061035156
Ref: 10-F763334
| 1g | Discontinued | Request information | |
| 250mg | Discontinued | Request information | |
| 500mg | Discontinued | Request information |
